NMRANeumora Therapeutics Inc.

NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations PR Newswire NEW YORK, June 17, 2026 Neumora Therapeutics...

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) PR Newswire NEW YORK, June 16...

NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.

The company described the results as disappointing and added that it is immediately discontinuing development of navacaprant.

Neumora Therapeutics (NASDAQ:NMRA) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-neumora-therapeutics-inc-stock...

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the firm, Marketbeat reports...

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities researchers at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a...

Guggenheim reiterated a "buy" rating and issued a $14.00 target price on shares of Neumora Therapeutics in a report on Tuesday...

Needham & Company LLC reissued a "buy" rating and issued a $8.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday...